{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:08:15Z","timestamp":1784736495795,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","award":["AISG-GC-2019-002"],"award-info":[{"award-number":["AISG-GC-2019-002"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"MOH | National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-OFLCG18May-0028"],"award-info":[{"award-number":["MOH-OFLCG18May-0028"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The digital revolution in healthcare, amplified by the COVID-19 pandemic and artificial intelligence (AI) advances, has led to a surge in the development of digital technologies. However, integrating digital health solutions, especially AI-based ones, in rare diseases like Waldenstr\u00f6m macroglobulinemia (WM) remains challenging due to limited data, among other factors. CURATE.AI, a clinical decision support system, offers an alternative to big data approaches by calibrating individual treatment profiles based on that individual\u2019s data alone. We present a case study from the PRECISE CURATE.AI trial with a WM patient, where, over two years, CURATE.AI provided dynamic Ibrutinib dose recommendations to clinicians (users) aimed at achieving optimal IgM levels. An 80-year-old male with newly diagnosed WM requiring treatment due to anemia was recruited to the trial for CURATE.AI-based dosing of the Bruton tyrosine kinase inhibitor Ibrutinib. The primary and secondary outcome measures were focused on scientific and logistical feasibility. Preliminary results underscore the platform\u2019s potential in enhancing user and patient engagement, in addition to clinical efficacy. Based on a two-year-long patient enrollment into the CURATE.AI-augmented treatment, this study showcases how AI-enabled tools can support the management of rare diseases, emphasizing the integration of AI to enhance personalized therapy.<\/jats:p>","DOI":"10.1038\/s41746-024-01195-5","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:02:47Z","timestamp":1724752967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Personalized dose selection for the first Waldenstr\u00f6m macroglobulinemia patient on the PRECISE CURATE.AI trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0727-7611","authenticated-orcid":false,"given":"Agata","family":"Blasiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester W. J.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3742-2704","authenticated-orcid":false,"given":"Li Ming","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-826X","authenticated-orcid":false,"given":"Xavier","family":"Tadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T. L.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-5879","authenticated-orcid":false,"given":"Kirthika","family":"Senthil Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6797-7850","authenticated-orcid":false,"given":"Yoann","family":"Sapanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-1368","authenticated-orcid":false,"given":"Raghav","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"de Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7337-296X","authenticated-orcid":false,"given":"Dean","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"1195_CR1","unstructured":"Open Knowledge Repository. Digital-in-health: unlocking the value for everyone. http:\/\/hdl.handle.net\/10986\/40212 (2023)."},{"key":"1195_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cvdhj.2020.12.002","volume":"2","author":"H Dohse","year":"2021","unstructured":"Dohse, H. Patient perspective: wearable and digital health tools to support managing our health during the COVID-19 pandemic and beyond. Cardiovasc. Digit. Health J. 2, 88 (2021).","journal-title":"Cardiovasc. Digit. Health J."},{"key":"1195_CR3","doi-asserted-by":"publisher","first-page":"e0238658","DOI":"10.1371\/journal.pone.0238658","volume":"15","author":"Z Gy\u0151rffy","year":"2020","unstructured":"Gy\u0151rffy, Z., Rad\u00f3, N. & Mesko, B. Digitally engaged physicians about the digital health transition. PLoS ONE 15, e0238658 (2020).","journal-title":"PLoS ONE"},{"key":"1195_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaz3023","volume":"367","author":"D Ho","year":"2020","unstructured":"Ho, D. Artificial intelligence in cancer therapy. Science 367, 982\u2013983 (2020).","journal-title":"Science"},{"key":"1195_CR5","first-page":"295","volume":"284","author":"E Koski","year":"2021","unstructured":"Koski, E. & Murphy, J. AI in healthcare. Stud. Health Technol. Inform. 284, 295\u2013299 (2021).","journal-title":"Stud. Health Technol. Inform."},{"key":"1195_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1816 (2017).","journal-title":"Nat. Commun."},{"key":"1195_CR7","first-page":"1","volume":"43","author":"K Senthil Kumar","year":"2023","unstructured":"Senthil Kumar, K. et al. Artificial intelligence in clinical oncology: from data to digital pathology and treatment. Am. Soc. Clin. Oncol. Educ. Book 43, 1\u201316 (2023).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1195_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-5-88","volume":"5","author":"I Al-Shyoukh","year":"2011","unstructured":"Al-Shyoukh, I. et al. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst. Biol. 5, 88 (2011).","journal-title":"BMC Syst. Biol."},{"key":"1195_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.201800104","volume":"1","author":"AJ Pantuck","year":"2018","unstructured":"Pantuck, A. J. et al. Modulating BET bromodomain inhibitor ZEN\u20103694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform. Adv. Ther. 1, 1800104 (2018).","journal-title":"Adv. Ther."},{"key":"1195_CR10","doi-asserted-by":"publisher","first-page":"333ra349","DOI":"10.1126\/scitranslmed.aac5954","volume":"8","author":"A Zarrinpar","year":"2016","unstructured":"Zarrinpar, A. et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci. Transl. Med. 8, 333ra349 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1195_CR11","doi-asserted-by":"publisher","first-page":"e077219","DOI":"10.1136\/bmjopen-2023-077219","volume":"13","author":"A Remus","year":"2023","unstructured":"Remus, A. et al. Protocol: CURATE. AI COR-Tx platform as a digital therapy and digital diagnostic for cognitive function in patients with brain tumour postradiotherapy treatment: protocol for a prospective mixed-methods feasibility clinical trial. BMJ Open 13, e077219 (2023).","journal-title":"BMJ Open"},{"key":"1195_CR12","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1021\/acsnano.5b00638","volume":"9","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9, 3332\u20133344 (2015).","journal-title":"ACS Nano"},{"key":"1195_CR13","doi-asserted-by":"crossref","unstructured":"Blasiak, A. et al. The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens. NPJ Digit. Med. 5, (2022).","DOI":"10.1038\/s41746-022-00627-4"},{"key":"1195_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/2211068215579612","volume":"20","author":"MB Mohd Abdul Rashid","year":"2015","unstructured":"Mohd Abdul Rashid, M. B. et al. Identification and optimization of combinatorial glucose metabolism inhibitors in hepatocellular carcinomas. J. Lab. Autom. 20, 423\u2013437 (2015).","journal-title":"J. Lab. Autom."},{"key":"1195_CR15","doi-asserted-by":"publisher","first-page":"1900127","DOI":"10.1002\/adtp.201900127","volume":"3","author":"X Ding","year":"2020","unstructured":"Ding, X. et al. Harnessing an artificial intelligence platform to dynamically individualize combination therapy for treating colorectal carcinoma in a rat model. Adv. Ther. 3, 1900127 (2020).","journal-title":"Adv. Ther."},{"key":"1195_CR16","doi-asserted-by":"publisher","first-page":"eaan0941","DOI":"10.1126\/scitranslmed.aan0941","volume":"10","author":"MB Mohd Abdul Rashid","year":"2018","unstructured":"Mohd Abdul Rashid, M. B. et al. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). Sci. Transl. Med. 10, eaan0941 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1195_CR17","doi-asserted-by":"publisher","first-page":"B023","DOI":"10.1158\/1538-7445.CancEpi22-B023","volume":"82","author":"JYH Goh","year":"2022","unstructured":"Goh, J. Y. H., De Mel, S., Rashid, M., Jeyasekharan, A. & Chow, E. K. -H. Abstract B023: Personalized phenotypic ex vivo drug sensitivity platform identifies frequent HDAC inhibitor-based combination sensitivities in T-cell lymphomas. Cancer Res. 82, B023\u2013B023 (2022).","journal-title":"Cancer Res."},{"key":"1195_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/2211068216681979","volume":"22","author":"D-K Lee","year":"2017","unstructured":"Lee, D. -K., Chang, V. Y., Kee, T., Ho, C. -M. & Ho, D. Optimizing combination therapy for acute lymphoblastic leukemia using a phenotypic personalized medicine digital health platform: Retrospective optimization individualizes patient regimens to maximize efficacy and safety. SLAS Technol. 22, 276\u2013288 (2017).","journal-title":"SLAS Technol."},{"key":"1195_CR19","doi-asserted-by":"publisher","first-page":"333ra49","DOI":"10.1126\/scitranslmed.aac5954","volume":"8","author":"A Zarrinpar","year":"2016","unstructured":"Zarrinpar, A. et al. Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform. Sci. Transl. Med. 8, 333ra49 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1195_CR20","doi-asserted-by":"publisher","first-page":"2170030","DOI":"10.1002\/adtp.202170030","volume":"4","author":"ATL Truong","year":"2021","unstructured":"Truong, A. T. L. et al. Harnessing CURATE.AI for N-of-1 optimization analysis of combination therapy in hypertension patients: A retrospective case series (Adv. Therap. 10\/2021). Adv. Ther. 4, 2170030 (2021).","journal-title":"Adv. Ther."},{"key":"1195_CR21","doi-asserted-by":"crossref","unstructured":"Chong, L. M. et al. Radiation therapy with phenotypic medicine: towards N-of-1 personalization. Br. J. Cancer 1\u201310 (2024).","DOI":"10.1038\/s41416-024-02653-3"},{"key":"1195_CR22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"1195_CR23","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo, J. J. et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol. 7, e827\u2013e837 (2020).","journal-title":"Lancet Haematol."},{"key":"1195_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ajh.26082","volume":"96","author":"MA Gertz","year":"2021","unstructured":"Gertz, M. A. Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am. J. Hematol. 96, 258\u2013269 (2021).","journal-title":"Am. J. Hematol."},{"key":"1195_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00916-5","volume":"13","author":"W-L Chan","year":"2023","unstructured":"Chan, W.-L. et al. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis. Blood Cancer J. 13, 140 (2023).","journal-title":"Blood Cancer J."},{"key":"1195_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03798-6","volume":"20","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstr\u00f6m macroglobulinemia. J. Transl. Med. 20, 576 (2022).","journal-title":"J. Transl. Med."},{"key":"1195_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"1195_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1002-z","volume":"14","author":"CMW Gaasterland","year":"2019","unstructured":"Gaasterland, C. M. W. et al. The patient\u2019s view on rare disease trial design \u2013 a qualitative study. Orphanet J. Rare Dis. 14, 31 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"1195_CR29","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1002\/jcph.2134","volume":"62","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Natural history and real\u2010world data in rare diseases: applications, limitations, and future perspectives. J. Clin. Pharmacol. 62, S38\u2013S55 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"1195_CR30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1182\/blood-2014-03-565135","volume":"124","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos, M. A. et al. Treatment recommendations for patients with Waldenstr\u00f6m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 124, 1404\u20131411 (2014).","journal-title":"Blood"},{"key":"1195_CR31","doi-asserted-by":"publisher","unstructured":"Abeykoon, J. P. et al. Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenstr\u00f6m macroglobulinemia (WM): an international collaborative study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7566 (2022).","DOI":"10.1200\/JCO.2022.40.16_suppl.7566"},{"key":"1195_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592891","volume":"10","author":"F Francescangeli","year":"2020","unstructured":"Francescangeli, F. et al. COVID-19\u2013Induced modifications in the tumor microenvironment: do they affect cancer reawakening and metastatic relapse? Front. Oncol. 10, 592891 (2020).","journal-title":"Front. Oncol."},{"key":"1195_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/EDBK_319567","volume":"41","author":"SL Groenland","year":"2021","unstructured":"Groenland, S. L., Ratain, M. J., Chen, L. S. & Gandhi, V. The right dose: from phase I to clinical practice. Am. Soc. Clin. Oncol. Educ. Book 41, 92\u2013106 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1195_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/aisy.202200056","volume":"4","author":"M Egermark","year":"2022","unstructured":"Egermark, M., Blasiak, A., Remus, A., Sapanel, Y. & Ho, D. Overcoming pilotitis in digital medicine at the intersection of data, clinical evidence, and adoption. Adv. Intell. Syst. 4, 2200056 (2022).","journal-title":"Adv. Intell. Syst."},{"key":"1195_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41746-023-00764-4","volume":"6","author":"S Xiong","year":"2023","unstructured":"Xiong, S. et al. Digital health interventions for non-communicable disease management in primary health care in low-and middle-income countries. npj Digit. Med. 6, 12 (2023).","journal-title":"npj Digit. Med."},{"key":"1195_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s42256-023-00670-0","volume":"5","author":"Z Jia","year":"2023","unstructured":"Jia, Z. et al. The importance of resource awareness in artificial intelligence for healthcare. Nat. Mach. Intell. 5, 687\u2013698 (2023).","journal-title":"Nat. Mach. Intell."},{"key":"1195_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41746-023-00918-4","volume":"6","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. A translational perspective towards clinical AI fairness. npj Digit. Med. 6, 172 (2023).","journal-title":"npj Digit. Med."},{"key":"1195_CR38","doi-asserted-by":"publisher","first-page":"e0213067","DOI":"10.1371\/journal.pone.0213067","volume":"14","author":"A Wernhart","year":"2019","unstructured":"Wernhart, A., Gahbauer, S. & Haluza, D. eHealth and telemedicine: practices and beliefs among healthcare professionals and medical students at a medical university. PLoS ONE 14, e0213067 (2019).","journal-title":"PLoS ONE"},{"key":"1195_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2021.635524","volume":"3","author":"BKJ Tan","year":"2021","unstructured":"Tan, B. K. J. et al. Personalised, rational, efficacy-driven cancer drug dosing via an artificial intelligence systEm (PRECISE): a protocol for the PRECISE CURATE.AI pilot clinical trial. Front. Digit. Health 3, 635524 (2021).","journal-title":"Front. Digit. Health"},{"key":"1195_CR40","doi-asserted-by":"publisher","first-page":"e48476","DOI":"10.2196\/48476","volume":"10","author":"S Vijayakumar","year":"2023","unstructured":"Vijayakumar, S. et al. Doctor perceptions towards AI in CDSS: a qualitative study of the CURATE.AI a personalised dose optimization platform. JMIR Hum. Factors 10, e48476 (2023).","journal-title":"JMIR Hum. Factors"},{"key":"1195_CR41","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41746-023-00906-8","volume":"6","author":"IG Cohen","year":"2023","unstructured":"Cohen, I. G. et al. How AI can learn from the law: putting humans in the loop only on appeal. npj Digit. Med. 6, 160 (2023).","journal-title":"npj Digit. Med."},{"key":"1195_CR42","unstructured":"Wilkinson, T., Wang, M., Friedman, J. & G\u00f6rgens, M. A. Framework for the economic evaluation of digital health interventions. World Bank Policy Research Working Paper Series https:\/\/documents1.worldbank.org\/curated\/en\/099446504122313917\/pdf\/IDU0f639726d0f11404a3509af8054677649dcd6.pdf (2023)."},{"key":"1195_CR43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jamia\/ocad040","volume":"30","author":"NM White","year":"2023","unstructured":"White, N. M. et al. Evaluating the costs and consequences of computerized clinical decision support systems in hospitals: a scoping review and recommendations for future practice. J. Am. Med. Inform. Assoc. 30, 1205\u20131218 (2023).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1195_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/amiajnl-2011-000113","volume":"18","author":"A Wright","year":"2011","unstructured":"Wright, A. et al. Development and evaluation of a comprehensive clinical decision support taxonomy: comparison of front-end tools in commercial and internally developed electronic health record systems. J. Am. Med. Inform. Assoc. 18, 232\u2013242 (2011).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1195_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41746-020-0221-y","volume":"3","author":"RT Sutton","year":"2020","unstructured":"Sutton, R. T. et al. An overview of clinical decision support systems: benefits, risks, and strategies for success. npj Digit. Med. 3, 17 (2020).","journal-title":"npj Digit. Med."},{"key":"1195_CR46","doi-asserted-by":"crossref","unstructured":"Hult, K. J. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments. in Economic Dimensions of Personalized and Precision Medicine (eds Berndt, E. R., Goldman, D. P. & Rowe, J.) 185-216 (National Bureau of Economic Research, 2018).","DOI":"10.7208\/chicago\/9780226611235.003.0007"},{"key":"1195_CR47","unstructured":"Hult, K. J. Incremental Innovation and Pharmaceutical Productivity. PhD thesis, the University of Chicago (2015)."},{"key":"1195_CR48","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown, J. R. et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102, 1796 (2017).","journal-title":"Haematologica"},{"key":"1195_CR49","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato, A. R. et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 103, 874 (2018).","journal-title":"Haematologica"},{"key":"1195_CR50","doi-asserted-by":"publisher","first-page":"e17045","DOI":"10.2196\/17045","volume":"21","author":"D deBronkart","year":"2019","unstructured":"deBronkart, D. & Eysenbach, G. Gimme my damn data (and let patients help!): the# GimmeMyDamnData manifesto. J. Med. Internet Res. 21, e17045 (2019).","journal-title":"J. Med. Internet Res."},{"key":"1195_CR51","doi-asserted-by":"publisher","first-page":"e39178","DOI":"10.2196\/39178","volume":"24","author":"B Mesk\u00f3","year":"2022","unstructured":"Mesk\u00f3, B. & deBronkart, D. Patient design: the importance of including patients in designing health care. J. Med. Internet Res. 24, e39178 (2022).","journal-title":"J. Med. Internet Res."},{"key":"1195_CR52","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1200\/JCO.1998.16.7.2305","volume":"16","author":"CK Daugherty","year":"1998","unstructured":"Daugherty, C. K. et al. Study of cohort-specific consent and patient control in phase I cancer trials. J. Clin. Oncol. 16, 2305\u20132312 (1998).","journal-title":"J. Clin. Oncol."},{"key":"1195_CR53","doi-asserted-by":"publisher","first-page":"e47094","DOI":"10.2196\/47094","volume":"25","author":"Y Sapanel","year":"2023","unstructured":"Sapanel, Y. et al. Economic evaluation associated with clinical-grade mobile app\u2013based digital therapeutic interventions: systematic review. J. Med. Internet Res. 25, e47094 (2023).","journal-title":"J. Med. Internet Res."},{"key":"1195_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13012-017-0701-x","volume":"13","author":"R Tamblyn","year":"2018","unstructured":"Tamblyn, R., Winslade, N., Qian, C. J., Moraga, T. & Huang, A. What is in your wallet? A cluster randomized trial of the effects of showing comparative patient out-of-pocket costs on primary care prescribing for uncomplicated hypertension. Implement. Sci. 13, 1\u201314 (2018).","journal-title":"Implement. Sci."},{"key":"1195_CR55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41591-022-01772-9","volume":"28","author":"B Vasey","year":"2022","unstructured":"Vasey, B. et al. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat. Med. 28, 924\u2013933 (2022).","journal-title":"Nat. Med."},{"key":"1195_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7453\/gahmj.2013.008","volume":"2","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier, J. J. et al. The CARE guidelines: consensus-based clinical case reporting guideline development. Glob. Adv. Health Med. 2, 38\u201343 (2013).","journal-title":"Glob. Adv. Health Med."},{"key":"1195_CR57","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01195-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01195-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T10:19:28Z","timestamp":1724753968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01195-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1038\/s41746-024-01195-5","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. discloses equity in KYAN Therapeutics. R.S. discloses support from Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, Eli Lilly, Roche, AstraZeneca, DKSH, MSD, Paxman Coolers, Natera, Astellas, GSK, Ipsen outside the submitted work. S.D.M. reports roles in the Advisory board for Amgen and Pfizer, not related to the drugs discussed in this manuscript. A.B., A.T.L.T., L.W.J.T., K.S.K., S.-B.T., and D.H. are coinventors of previously filed pending patent(s) on AI\u2013based therapy development. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}